22.02.2023 - Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company’s Biologics License Application (BLA) for elranatamab, an investigational B-cell maturation antigen (BCMA) . Seite 1
FDA, EMA Accept Pfizer s Elranatamab Filing miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) announced the FDA has granted Priority Review for the company's Biologics License Application for elranatamab for the treatment of patients with relapsed
Breaking Through in Advanced Prostate Cancer bbc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bbc.com Daily Mail and Mail on Sunday newspapers.